Introduction {#Sec1}
============

Hepatic resection remains an important curative treatment for hepatocellular carcinoma (HCC). Nonetheless, postresection tumor recurrence is common with a 5-year recurrence rate of \>50% \[[@CR1], [@CR2]\]. The treatment algorithm for recurrent HCC varies from center to center, and there is not yet a consensus on the most appropriate treatment for postresection tumor recurrence. Nonsurgical treatment such as transarterial oily chemoembolization is, at best, a palliative treatment after which long-term survival is seldom observed \[[@CR3], [@CR4]\]. Salvage transplantation probably produces the best survival results as it removes both the tumor and the cirrhotic liver \[[@CR5], [@CR6]\]. However, a shortage of liver grafts, stringent patient selection criteria, and a normal liver biochemical profile that constitutes a low Model for End-stage Liver Disease score often relegate patients with recurrent HCC to the least priority to receive a graft before the disease progresses. Re-resection would be an ideal alternative, which was shown to be an effective approach to prolong survival \[[@CR7]\], but its feasibility is limited by the small liver remnant and inadequate liver function reserve. Another treatment option is radiofrequency ablation (RFA), which that is applicable even to patients with borderline liver function and can be delivered via the percutaneous as well as the open approach. The aim of this study was to determine if RFA or re-resection is the preferred treatment modality for the management of intrahepatic recurrence after hepatectomy for HCC.

Patients and methods {#Sec2}
====================

From January 2001 to December 2008, 669 patients underwent hepatic resection for HCC at the Department of Surgery in Queen Mary Hospital, The University of Hong Kong. At the time of the data analysis, 257 patients remained free of recurrence, 179 patients had developed intrahepatic recurrence, 115 patients haddeveloped extrahepatic recurrence, and 118 patients had developed both. Among the 179 patients with intrahepatic recurrence, 74 patients underwent either re-resection or RFA as the secondary treatment, and they formed the focus of interest in this study. Prospectively collected data on patient characteristics, clinicopathologic features, and survival outcomes were reviewed.

Diagnostic criteria for recurrent HCC {#Sec3}
-------------------------------------

The follow-up protocol for patients after hepatectomy for primary HCC in our center consisted of computed tomography (CT) or magnetic resonance imaging (MRI) of the liver 1 month after hepatic resection to confirm macroscopic tumor clearance. Thereafter, surveillance for tumor recurrence was conducted using CT or MRI scans of the liver every 3 months with serial measurements of serum α-fetoprotein (AFP) and liver biochemistry. Intrahepatic recurrence is defined as a new lesion with arterial enhancement and portal venous washout on contrast-enhanced CT or MRI scans with or without an elevated serum AFP level (\>200 ng/ml).

Selection criteria for re-resection or RFA as a secondary treatment {#Sec4}
-------------------------------------------------------------------

Only patients with Child-Pugh class A cirrhosis and selected patients with Child-Pugh class B cirrhosis were considered for re-resection or RFA. The usual indication for re-resection was a solitary or oligonodular tumor irrespective of tumor size within a monosegment of liver in the presence of a sufficient future liver remnant. It was generally avoided in the presence of (1) gross ascites, and/or (2) an indocyanine green retention rate of \>15% at 15 min, and/or (3) a platelet count \<100 × 10^9^/L, signifying severe portal hypertension. RFA was selected when the recurrent tumor was (1) \<6 cm or there were three or fewer tumor nodules, and/or (2) in a deep-seated intraparenchymal location where anatomic re-resection would remove more than one segment of liver, leading to insufficient remnant liver volume. Needle biopsy for histologic confirmation was performed before application of RFA, and the tract was subsequently ablated on withdrawal of the RFA probe. The percutaneous approach was usually considered first (*n* = 22) unless the tumor was situated near the gallbladder or the bowel loops or when there was difficulty localizing the tumor with transabdominal ultrasonography. The open or laparoscopic approach was selected otherwise (*n* = 23).

Statistical analysis {#Sec5}
--------------------

Continuous variables were expressed in medians (interquartile range) and compared using the Mann--Whitney *U*-test. Categoric variables were compared with the χ^2^ test or Fisher's exact test when appropriate. Overall survival and disease-free survival of the two study groups were estimated by the Kaplan-Meier method. Comparison of survival between groups was performed with the log-rank test. Disease-free survival after treatment of intrahepatic recurrence was defined as the period from the date of treatment of recurrent HCC to the date of the second tumor recurrence or death. Overall survival after hepatectomy was defined as the period from the date of hepatectomy for the primary HCC to the date of death related to any cause. Overall survival after treatment of intrahepatic recurrence was defined as the period from the date of treatment for the first recurrence to the date of death related to any cause. A *p* value ≤0.05 was considered to be significant. Statistical analysis was performed using the SPSS 16.0 computer software program.

Results {#Sec6}
=======

The median follow-up duration was 44.9 months (8.3--112.0 months). Table [1](#Tab1){ref-type="table"} shows the patients' characteristics and liver function profiles at the time of the intrahepatic recurrence. Patients in the RFA group were older than those in the re-resection group. The two groups had a similar incidence of co-morbid illness and similar viral hepatitis carrier rates. All patients in the re-resection group had Child-Pugh class A cirrhosis, whereas 88.9% of patients in the RFA group were of Child-Pugh class A and 11.1% were of Child-Pugh class B (*p* = 0.17). Pretreatment liver biochemistry and renal function at the time of recurrence were comparable for the two groups except that patients in the RFA group had a higher serum bilirubin level and a lower serum albumin level. With regard to the pathology of the primary HCC (Table [2](#Tab2){ref-type="table"}), the two groups shared similar features in terms of tumor nodularity, degree of tumor cell differentiation, and distribution of tumor staging \[American Joint Committee on Cancer (AJCC) 6th edition). The RFA group, however, had a larger primary tumor size than the re-resection group (5.5 vs. 3.5 cm, *p* = 0.01), suggesting that tumors in the former group might be more aggressive. Time to develop first recurrence was longer in the re-resection group, although the difference was not statistically significant (12.2 vs. 8.7 months, *p* = 0.84). Pathological characteristics of recurrent tumors (Table [3](#Tab3){ref-type="table"}) were similar in the two groups in terms of tumor size (*p* = 0.73), tumor nodularity (*p* = 0.48), and serum AFP level (*p* = 0.85). Table [4](#Tab4){ref-type="table"} showed the postoperative outcomes of patients undergoing re-resection and RFA via the open or laparoscopic approach (*n* = 23). Seven patients developed a total of 11 procedure-related morbidities in the re-resection group, with most of them Dindo-Clavien grade II. One patient in the RFA group developed aggressive lymphoproliferative disease after open RFA and succumbed during the same hospital admission. The incidences of procedure-related morbidity (*p* = 0.27) and hospital mortality (*p* = 0.91) were not statistically different for the two groups.Table 1Patient characteristics and liver function profile at the time of recurrence after hepatectomyCharacteristicRe-resection (*n* = 29)RFA (*n* = 45)*p*Age (years)52 (38--79)59 (36--80)0.03Co-morbid illness11 (37.9%)23 (51.1%)0.27Carrier of hepatitis B virus26 (89.7%)40 (88.9%)1.00Carrier of hepatitis C virus1 (3.6%)3 (7.1%)0.39Child-Pugh class A29 (100%)40 (88.9%)0.17Child-Pugh class B05 (11.1%)Serum bilirubin (μmol/L)11 (6--35)14 (5--61)0.02Serum alanine transaminase (μ/L)51 (17--99)47.5 (12--379)0.83Serum aspartate transaminase (μ/L)48 (19--77)43 (20--177)0.76Serum albumin (g/dl)41 (28--48)39 (25--49)0.03Platelet count (×10^9^/L)136 (79--270)142 (46--291)0.83Serum urea (mmol/L)4.9 (2.6--10.5)5.4 (2.6--20.6)0.23Serum creatinine (μmol/L)82 (44--137)89 (49--185)0.23Nontumorous liver parenchyma Normal4 (13.8%)5 (11.1%)0.17 Chronic hepatitis/cirrhosis25 (86.2%)40 (88.9%)*RFA* radiofrequency ablationTable 2Pathologic features of primary HCCFeatureRe-resection (*n* = 29)RFA (*n* = 45)*p*Primary tumor size (cm)3.5 (1.0--14.5)5.5 (1.5--22.0)0.01No. of tumor nodules1 (1--3)1 (1--multiple)0.11Tumor cell differentiation^a^0.86 Well differentiation4 (13.8%)8 (17.8%) Moderate differentiation21 (72.4%)29 (64.4%) Poor differentiation4 (13.8%)6 (13.3%)Serum α-fetoprotein (ng/ml)64 (2--167,138)90 (1--197,122)0.85AJCC stage0.12 I12 (41.4%)18 (40.0%) II15 (51.7%)19 (42.2%) III2 (6.9%)8 (17.8%)*HCC* hepatocellular carcinoma, *AJCC* American Joint Committee on Cancer^a^Two patients in the RFA group had a sampling error in the tumor biopsy specimenTable 3Tumor characteristics of intrahepatic HCC recurrenceCharacteristicRe-resection (*n* = 29)RFA (*n* = 45)*p*Time to recurrence (months)12.2 (1.8--84.3)8.7 (1.0--88.5)0.84Tumor size (cm)2.1 (0.8--5.5)2.2 (0.8--6.0)0.73Solitary tumor recurrence21 (72.4%)29 (64.4%)0.48Serum α-fetoprotein (ng/ml)64 (2--167,138)90 (1--197,122)0.85Table 4Postoperative outcomes after treatment of recurrent HCCOutcomeRe-resection (*n* = 29)Open RFA (*n* = 23)*p*Postoperative morbidities (no.)7 (24.1%)2 (8.7%)0.27 Pleural effusion510.33 Pneumonia111.00 Wound infection300.32 Intraabdominal hemorrhage101.0 Septicemia101.0Hospital mortality (no.)010.91Dindo-Clavien classification \[[@CR20]\] II82 IIIa10 IIIb10 IVa10 V01

Table [5](#Tab5){ref-type="table"} illustrates the patterns of the second recurrence in the two groups after treatment of the first intrahepatic recurrence and the subsequent management. At the time of analysis, 27.6% of the patients in the re-resection group and 15.6% of the patients in the RFA group remained free of recurrence. The time to develop a second recurrence was 5.9 months in the re-resection group and 4.0 months in the RFA group (*p* = 0.30). By excluding tumors with a positive re-resection margin (*n* = 3, 10.3%) and tumors that were incompletely ablated (*n* = 14, 31.1%) during treatment for the first recurrence, the times to develop a second recurrence in the re-resection group and the RFA group was extended to 6.3 months and 9.5 months, respectively (*p* = 0.25). The 1-, 3-, and 5-year overall survival rates from the time of hepatectomy for primary HCC in the re-resection group were 89.7%, 82.3%, and 55.7%, respectively. The RFA group had corresponding rates of 95.6%, 68.2%, and 44.5% (Fig. [1](#Fig1){ref-type="fig"}). The 1-, 3-, and 5-year overall survival rates after treatment of the first intrahepatic recurrence in the re-resection group were 89.7%, 56.5%, and 35.2%, respectively. The RFA group had corresponding rates of 83.7%, 43.1%, and 29.1% (Fig. [2](#Fig2){ref-type="fig"}). The 1-, 3-, and 5-year disease-free survival rates after treatment of the first intrahepatic recurrence in the re-resection group were 41.4%, 24.2%, and 24.2%, respectively. The corresponding rates in the RFA group were 32.2%, 12.4%, and 9.3% (Fig. [3](#Fig3){ref-type="fig"}).Table 5Recurrence pattern and subsequent management after treatment of intrahepatic recurrenceRecurrenceRe-resection (*n* = 29)RFA (*n* = 45)*p*Recurrence pattern0.23 No recurrence8 (27.6%)7 (15.6%) Intrahepatic only13 (44.8%)19 (42.2%) Extrahepatic only2 (6.9%)1 (2.2%) Intrahepatic and extrahepatic6 (20.7%)18 (40.0%)Treatment of second intrahepatic recurrence0.66 Alcohol injection1 (7.7%)0 (0%) Transarterial oily chemoembolization5 (38.5%)4 (21.1%) Re-resection1 (7.7%)3 (15.8%) Liver transplantation01 (5.3%) Systemic chemotherapy01 (5.3%) RFA3 (23.1%)5 (26.3%) Conservative3 (23.1%)5 (26.3%)Fig. 1Overall survival after hepatectomy for primary hepatocellular carcinoma. *RFA* radiofrequency ablationFig. 2Overall survival after treatment of intrahepatic recurrenceFig. 3Disease-free survival after treatment of intrahepatic recurrence

Univariate analysis of nine clinical parameters (Table [6](#Tab6){ref-type="table"}) showed that time to the first intrahepatic recurrence after hepatectomy, time to the second recurrence after treatment of the first intrahepatic recurrence, and recurrence in more than one organ after treatment of the first intrahepatic recurrence were significant clinical factors that adversely affected overall survival after hepatectomy for primary HCC. In the multivariate analysis, only recurrence in more than one organ after treatment of the first intrahepatic recurrence remained an independent unfavorable prognostic factor for overall survival (*p* \< 0.001, hazard ratio 4.424, confidence interval 2.313--8.462).Table 6Univariate analysis identifying prognostic factors for overall survival after hepatectomyClinical parameterMedian survival (months)*p*Age (years)0.18 ≤55 (*n* = 38)51.20 \>55 (*n* = 36)76.70Tumor size (cm)0.26 ≤5.0 (*n* = 46)66.97 \>5.0 (*n* = 28)59.22Viral hepatitis positivity0.56 Hepatitis B (*n* = 66)55.24 Hepatitis C (*n* = 4)76.70Child-Pugh classification0.78 A (*n* = 70)59.97 B (*n* = 4)16.92Re-resection0.19 Yes (*n* = 33)88.70 No (*n* = 41)46.07Time to first intrahepatic recurrence\< 0.001 ≤12 months (*n* = 38)6.67 \>12 months (*n* = 36)36.12Time to second tumor recurrence\< 0.001 ≤12 months (*n* = 21)5.29 \>12 months (*n* = 19)30.23Single-site recurrence^a^\< 0.001 Yes (*n* = 48)\> 112.03 No (*n* = 26)36.64Intrahepatic recurrence0.29 Solitary (*n* = 50)61.2 Multiple (*n* = 24)46.1^a^Denotes recurrence in one organ after treatment of a first intrahepatic recurrence

Discussion {#Sec7}
==========

With the refinement in preoperative liver function assessment \[[@CR8]\] and surgical techniques for hepatectomy over the past decade leading to decreased postoperative morbidity and mortality \[[@CR9], [@CR10]\], more patients with cirrhotic livers are now amenable to major hepatectomy. Nonetheless, postresection tumor recurrence is common, with a 5-year recurrence rate \>50% \[[@CR1], [@CR2], [@CR11], [@CR12]\]. In all, 80% of the recurrences develop within the liver remnant \[[@CR13]\], so it is important for surgeons to select the most appropriate treatment for patients with recurrent HCC. Cirrhosis is a known risk factor for intrahepatic recurrence \[[@CR1], [@CR13]\].

Treatment of intrahepatic recurrence poses several technical challenges, including a small liver remnant, inadequate liver function reserve, significant adhesion from a previous operation, and proximity of the tumor to major vascular or biliary structures. All of these conditions are relative contraindications to re-resection. The Kyoto group demonstrated a significant improvement in overall survival after active treatment of intrahepatic recurrence by either re-hepatectomy or RFA \[[@CR14]\]. However, their study did not explore the most appropriate choice of surgical treatment for intrahepatic recurrence.

Our study showed that RFA could achieve long-term survival outcomes similar to those seen with re-resection in patients with recurrent HCC. After excluding confounding factors (positive resection margin, incomplete ablation) for further intrahepatic recurrence, the survival benefit of RFA remained unchanged. There are several reasons why RFA should be the preferred treatment option for intrahepatic recurrence. First, RFA can be delivered percutaneously, thereby avoiding a second operation. Second, RFA is applicable even to tumors proximal to major intrahepatic bile ducts. The practice of bile duct cooling (i.e., instillation of cold normal saline into the common bile duct via the cystic duct stump \[[@CR15]\] or nasobiliary drain \[[@CR16], [@CR17]\]) can protect the bile duct from damage by the heat-sink effect of RFA. In our experience, about 3.5% of the patients undergoing RFA required bile duct cooling, and no biliary complications were observed in these patients \[[@CR15]\]. Third, conservation of nontumorous liver parenchyma and negligible blood loss associated with RFA minimize the degree of surgical insult to the small and cirrhotic liver remnant. Fourth, repeatability is a major advantage of RFA. Our study showed that 26.3% of patients in the RFA group and 23.1% of patients in the re-resection group underwent RFA for their second intrahepatic recurrence, whereas less than a fifth of the patients in the RFA group and re-resection group were amenable to repeated resection for second intrahepatic recurrence. These four factors contribute to the safety and feasibility of RFA in the management of intrahepatic recurrence after hepatectomy.

Despite the fact that the chance of survival was improved by further surgical treatment, early first intrahepatic recurrence after hepatectomy, early second intrahepatic recurrence after either RFA or re-resection, and second recurrence in more than one organ remained poor prognostic factors for overall survival in patients with recurrent HCC after hepatectomy. Further research should therefore focus on adjuvant treatment after resection of a primary HCC. In fact, our recent study demonstrated the survival benefit of postresection antiviral therapy in antiviral-naive patients with early staged tumors \[[@CR18]\]. Alternatively, results from the STORM trial \[[@CR19]\] might identify a new avenue in the area of adjuvant treatment for HCC in the future.

Our study design was not without pitfalls: a small sample size, nonrandomization regarding choices of treatment, and selection bias. However, a randomized controlled trial might not be practical as fewer than 50% of the patients with a first intrahepatic recurrence were eligible for further surgical treatment in this study.

Conclusions {#Sec8}
===========

Radiofrequency ablation achieved long-term survival outcome similar to those seen with re-resection in the treatment of intrahepatic recurrence after hepatectomy. Secondary treatment of recurrent HCC after hepatectomy remains a challenging issue for hepatobiliary surgeons. However, a persevering attitude is mandatory in the long-term management of HCC to improve the chance of treatment for recurrent disease. The fact that RFA can be delivered percutaneously and its high repeatability render it a preferred treatment option in selected patients with HCC recurrence.
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